GWAS insights can help link genes to pharmacologic treatments

Abstract

The genetic risk for psychiatric disorders may be separate from the way symptoms are currently targeted for certain pharmacologic treatments, according to a recent bioinformatic study. Rather, using the approach of a genome-wide association study (GWAS) could better link risk genes to the best pharmacologic treatments.